Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium
May 18th, 2021
2.3K views
The recombinant antibody protein expressed in pIRES2-ZSGreen1-rAbs-APN-CHO cells and monoclonal antibodies produced using traditional hybridoma technology can recognize and bind to the porcine aminopeptidase N (APN) protein.
Overview
This study focuses on the production and characterization of porcine aminopeptidase N (APN)-specific monoclonal antibodies (mAbs) using both traditional hybridoma technology and recombinant antibody expression methods. APN, a membrane-bound metallopeptidase, is a promising target for mucosal vaccines and therapeutics due to its role as a receptor for enterotoxigenic Escherichia coli F4 and transmissible gastroenteritis virus. The research compares the efficiency, specificity, and binding properties of mAbs generated by these two approaches, providing insights for future therapeutic development.
Key Study Components
Area of Science
- Immunology
- Monoclonal antibody production
- Protein expression and purification
Background
- APN is abundantly present in the small intestinal mucosa and can initiate mucosal immune responses.
- It serves as a receptor for certain bacterial and viral pathogens, making it a valuable target for vaccine and therapeutic development.
- Traditional hybridoma technology and recombinant expression systems are widely used for monoclonal antibody production.
- Efficient and reliable antibody production is critical for diagnostic and therapeutic applications.
Purpose of Study
- To compare the production of APN-specific monoclonal antibodies using hybridoma and recombinant expression methods.
- To establish and characterize stable CHO cell lines and E. coli strains expressing recombinant antibodies against APN.
- To evaluate the binding specificity and efficiency of the produced antibodies.
Methods Used
- Immunization of mice with APN protein and spleen cell collection.
- Hybridoma generation via fusion of spleen cells with SP20 myeloma cells using polyethylene glycol.
- Screening of hybridoma supernatants for APN-specific antibodies by ELISA.
- Recombinant antibody expression in E. coli BL21(DE3) and CHO cells using pET28a(+) and pIRES2-ZSGreen1 vectors, respectively.
- Selection of stably transfected CHO cells with G418 and fluorescence-activated cell sorting.
- Antibody purification using protein A agarose and characterization by SDS-PAGE, ELISA, and IFA assays.
Main Results
- Both hybridoma-derived and recombinant antibodies recognized and bound to APN protein.
- Hybridoma-derived mAbs showed various immunoglobulin subclasses and targeted different APN epitopes.
- Antibodies expressed in CHO cells (but not all recombinant systems) effectively recognized APN in binding assays.
- Protein A agarose purification yielded higher quality antibodies compared to ammonium sulfate precipitation.
Conclusions
- Recombinant antibody production can increase efficiency and reduce labor and time costs compared to traditional methods.
- Both production methods yield functional APN-specific antibodies suitable for further therapeutic development.
- The study provides a foundation for developing APN-targeted therapeutics and vaccines.
Frequently Asked Questions
What is the significance of porcine aminopeptidase N (APN) in immunology?
APN is a membrane-bound enzyme in the small intestine that can initiate mucosal immune responses and serves as a receptor for certain bacterial and viral pathogens, making it a valuable target for vaccine and therapeutic development.
How were APN-specific monoclonal antibodies produced in this study?
Antibodies were produced using both traditional hybridoma technology (fusion of immunized mouse spleen cells with myeloma cells) and recombinant expression in E. coli and CHO cells using specific plasmid vectors.
What methods were used to screen and characterize the antibodies?
Screening was performed using ELISA assays, and characterization included SDS-PAGE, isotyping, and immunofluorescence assays to confirm specificity and binding to APN.
What were the main differences observed between hybridoma-derived and recombinant antibodies?
Both types of antibodies recognized APN, but only antibodies expressed in CHO cells showed effective binding in certain assays. Hybridoma-derived antibodies displayed a range of immunoglobulin subclasses and epitope specificities.
Why is recombinant antibody production advantageous?
Recombinant production increases efficiency, scalability, and consistency, while reducing labor and time costs compared to traditional hybridoma methods.
How were stably transfected CHO cell lines established?
CHO cells were transfected with pIRES2-ZSGreen1-rAbs-APN plasmid, selected with G418, and sorted by fluorescence-activated cell sorting to isolate stable antibody-expressing clones.
What are the potential applications of the APN-specific antibodies developed in this study?
These antibodies can be used for developing antibody-drug conjugates, novel vaccines, and for further research into APN's role in mucosal immunity and pathogen interactions.
Executive Industry Relevance
Efficient production of monoclonal antibodies targeting porcine aminopeptidase N (APN) enables precise interrogation of mucosal immune mechanisms and supports the development of targeted therapeutics and vaccines. Comparative evaluation of hybridoma and recombinant expression systems informs pipeline decisions on antibody scalability, specificity, and downstream manufacturability. These capabilities are critical for advancing APN-targeted modalities and de-risking early-stage biotherapeutic portfolios.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables functional validation of APN as a mucosal immune target in porcine models.
- Supports mechanistic de-risking by generating antibodies against distinct APN epitopes.
- Facilitates pathway clarification for APN-mediated pathogen interactions.
- Provides tools for predictive confidence in target engagement studies.
Screening & Assay Development
- Delivers validated APN-specific antibodies for quantitative ELISA and immunofluorescence assays.
- Enables reproducible screening of antibody binding and specificity across platforms.
- Supports assay standardization for high-throughput evaluation of candidate therapeutics.
- Prepares scalable antibody sources for downstream screening workflows.
Translational & Preclinical Research
- Aligns antibody reagents with disease-relevant porcine mucosal models.
- Enables translational biomarker studies of APN in infection and immunity.
- Supports continuity from discovery through preclinical validation of APN-targeted interventions.
- Provides mechanistic insights for risk-adjusted advancement of APN-based therapeutics.
Pipeline & Workflow Integration
Monoclonal antibody generation against APN integrates into the discovery-to-preclinical continuum, supporting both target validation and translational research in mucosal immunology.
- Discovery Biology: Supplies critical reagents for hypothesis testing and mechanistic studies of APN function.
- Screening: Enables robust, quantitative assessment of antibody binding and epitope coverage.
- Analytics: Provides ELISA and immunofluorescence readouts for comparative analysis of antibody performance.
- Translational Research: Bridges discovery findings to preclinical models of infection and immunity.
- Enterprise Reuse: Establishes scalable antibody production platforms for future APN-targeted programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in APN as a therapeutic target and reduces mechanistic ambiguity.
- Operational Value: Improves standardization, reproducibility, and scalability of antibody production workflows.
- Strategic Value: Enables informed go/no-go decisions and enhances capital efficiency in early-stage programs.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of APN-targeted assets.
Implementation Considerations
- Requires expertise in hybridoma technology and recombinant antibody expression systems.
- Demands access to cell culture, protein purification, and analytical assay infrastructure.
- Necessitates cross-team standardization of antibody screening and validation protocols.
- May require adaptation for different species or mucosal model systems.
- Dependent on robust ELISA and immunofluorescence assay performance for quantitative outputs.
Biopharma FAQs
Why does null hypothesis testing matter for APN antibody target validation?
Null hypothesis testing using APN-specific monoclonal antibodies enables objective assessment of antibody binding specificity and functional relevance in mucosal models. This approach reduces false positives and increases confidence in APN as a validated therapeutic target.
How does independent variable isolation fit in APN antibody production workflows?
Isolating variables such as antibody subclass, epitope specificity, and expression system allows direct comparison of hybridoma and recombinant antibody outputs. This supports mechanistic de-risking and informs selection of optimal antibody candidates for further development.
What do quantitative ELISA and immunofluorescence measurements enable in APN antibody screening?
Quantitative ELISA and immunofluorescence assays provide reproducible metrics for antibody binding strength and specificity to APN. These measurements enable data-driven selection of high-performing clones and support downstream assay standardization.
Why are replication requirements critical for cross-functional antibody development teams?
Replication of antibody production and binding assays ensures reproducibility and reliability across teams, facilitating cross-functional collaboration and reducing risk of batch-to-batch variability in therapeutic development.
What statistical analysis capabilities are required before implementing APN antibody screening platforms?
Robust statistical analysis of ELISA and binding assay data is essential to distinguish true antibody-APN interactions from background noise. This enables confident advancement of validated antibody candidates into translational and preclinical pipelines.
Chapters in this video
0:04
Introduction
1:04
Hybridoma Technology to Produce Monoclonal Antibodies (mAbs) Against Aminopeptidase N (APN)
4:20
Expression of Recombinant Antibodies (rAbs) Against APN
6:25
Results: Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium
9:13
Conclusion
